和黃醫藥(00013.HK)治療轉移性結直腸癌藥物臨床顯示助降低死亡風險達34%
和黃醫藥(00013.HK)公布,將於巴黎時間下周一(12日)舉行的2022年歐洲腫瘤內科學會(ESMO)年會上,公布(口夫)(口奎)替尼(Fruquintinib)治療難治性的轉移性結直腸癌的FRESCO-2國際多中心III期研究數據總結。
FRESCO-2 國際多中心臨床試驗表明,與安慰劑相比,(口夫)(口奎)替尼療法在主要終點總生存期(OS)和關鍵次要終點無進展生存期(PFS)均達到具有統計學意義和臨床意義的顯著延長。(口夫)(口奎)替尼療法幫助降低轉移性結直腸癌的死亡風險達34%(0.66HR),更佳的疾病控制,疾病進展或死亡風險降低達68%(0.32HR)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.